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C++/CLI function calls. The interface connects to RayStation 
by identification of its process ID and setting up a pipe to its 
scripting client. The library handles the required memory 
conversions and communicates with a RayStation instance 
through direct IronPython calls. The NRC interface was tested 
by its integration in our in-house research TPS Dynaplan. 
Results: A clinical case for a prostate treatment was 
imported from the RayStation database into Dynaplan 
through the NRC interface. After the generation of a 
treatment plan in Dynaplan, the respective leaf 
configurations were sent to RayStation (through the NRC 
interface) and incorporated into a new plan and beam set. 
Subsequently a dose calculation request was sent to 
RayStation. An automatic window focus change to RayStation 
allowed for clinical approval of the dose distribution, which 




Conclusions: We successfully developed a library to interface 
the RayStation scripting API through native C++, allowing a 
risk decrease for the use of research software in a clinical 
environment. We could show by example how the NRC 
interface can be used in Dynaplan by exploiting the synergy 
of scripted access to a certified TPS and the power of 
traditional programming models. The legal implication on in-
house developed software used in combination with an API of 
a certified TPS will need to be further evaluated based on 
local and European legislation changes.  
   
EP-1441   
Evaluation of Eclipse Rapidplan for semi-automatic 
treatment planning of prostate radiation treatment 
M. Zamburlini1, J. Krayenbühl1, Y. Najafi1, S. Verlaan1, S. 
Graydon1, T. Streller1, S. Klöck1 
1University Hospital Zürich, Radiation Oncology, Zürich, 
Switzerland  
 
Purpose/Objective: Quality of modulated treatment plans is 
highly dependent on the planner skill and experience. Plan 
optimization is also a time consuming process which involves 
several iteration cycles before an acceptable plan is 
achieved. Rapidplan (Varian Medical System, USA) is a semi-
automated planning solution which promises to increase 
treatment planning efficiency and result in a more consistent 
plan quality as compared with individual manual 
optimization. The treatment planning process with Rapidplan 
relies on the creation of a model, obtained using high quality 
treatment plans previously optimized. A prostate model 
made available by Varian has been implemented in Eclipse 
(Varian Medical System, USA). The aim of this study was to 
compare the quality of plans created with the Eclipse 
prostate model and the model generated with plans from our 
institution with the manually optimized prostate plans. 
Materials and Methods: In total 40 post-operative prostate 
plans were retrospectively used in this study. Patients were 
planned with a dose fractionation 33x2Gy. 30 out of these 40 
plans were used to create an in-house prostate model. 
Varian’s prostate model and our model were used to re-
optimize ten prostate plans. The manual optimization was 
compared to the semi-automatic optimization obtained with 
the Varian and our prostate models. The comparison was 
done based on DVH parameters and MU. The target volume 
receiving 95% of the dose was compared between 
optimizations. The major OAR in postoperative prostate 
treatment is the rectum and at our institution it is paramount 
to achieve a high sparing of this OAR. The rectal volume 
receiving 40Gy (V40), 60 Gy (V60) and 65 Gy (V65) was 
compared between optimizations. Additionally the mean and 
max doses to the femoral heads were compared. 
Results: Rapidplan was easy and fast to use and no re-
optimization was required. The semiautomatic plans using 
the Varian prostate model reached a better PTV coverage 
respect to our plans (average V95 was 99.4% vs 97.2%). For 
the OAR, large dose differences were observed between 
Varian model optimized plans and our plans. Rectal V40, V60 
and V65 were in average 90%, 40% and 14% lower for the plan 
optimized by us than the one optimized using the Varian 
model, but the maximal dose to the femoral heads was in 
average 6 Gy higher. Total MU was in average 20% lower for 
the semi-automated optimized plans.  
Conclusions: Rapidplan is user friendly and requires less user 
input than manual optimization. The plan optimization and 
calculation was done at our station within 1 hour. Varian 
provides a prostate model which was developed by the 
Cancer Care Manitoba (Winnipeg – Canada) and it is based on 
the experience and treatment rationale in this clinic. We 
found that this model provided plans which are dosimetrically 
very different to what is currently expected and accepted in 
our clinic. Therefore our own model needed to be developed. 
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Purpose/Objective: Advanced RT techniques require 
conservative approaches to be taken due to a lack of detailed 
knowledge about treatment delivery uncertainties. For 
example, safety margins are added to target volumes and in-
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depth QA is performed for all components of the RT chain. 
Without a more thorough understanding of how these 
uncertainties impact treatment effectiveness, advanced 
techniques remain limited by this necessary cautious and 
safety-based approach. The aim of this pilot study was to 
develop a method to investigate how treatment delivery 
uncertainties affect patient dose distributions and to apply 
this method to a limited dataset of lung SABR plans. 
Materials and Methods: The Pinnacle3 TPS (version 9.8) was 
used to create reference 6 MV step and shoot IMRT plans for 
a lung SABR dataset on an Elekta Synergy linac with the MLCi 
MLC. Dose prescriptions were 50Gy/5fx, 54Gy/3fx and 
48Gy/4fx for central lung, free and near-rib tumours, 
respectively. Copies of the reference treatment plans were 
modified using in-house code to generate a series of 
systematic 'error-introduced' plans. The scripts altered the 
values of three beam delivery parameters (gantry angle, 
collimator angle and MLC leaf positions) across all control 
points. Gantry and collimator angles were changed from their 
reference values by ±1, 2 or 5 degrees. Changes to the 
planned MLC leaf positions were applied equally to all leaves 
such that each was shifted from its reference position by ±1, 
2 or 5 mm. Each error-introduced plan was then read back 
into Pinnacle and a dose calculation was performed on the 
reference patient anatomy. Target DVH metrics including 
V95%, V100% and V105% and OAR DVH metrics including Dmax 
for the heart and spinal column were extracted from all plans 
and compared to quantify differences between the reference 
and error-introduced dose distributions. 
Results: The PTV V100% and V105% tended to decrease with 
increasing magnitude of MLC leaf shift, with average 
decreases of 10 and 20% occurring respectively for MLC shifts 
of 5 mm. Dmax of the heart and spinal column increased up 
to 16 and 165% respectively when the modified gantry angles 
positioned incident beams closer to these OARs than in the 
reference plan. Collimator angle variation typically resulted 
in smaller deviations for all DVH metrics than variations in 
gantry angle or MLC leaf position. 
Conclusions: A method to investigate the impact of 
treatment delivery uncertainties on patient dose distributions 
has been developed and applied to an initial cohort of lung 
SABR plans. Target coverage was typically compromised more 
by changes in MLC leaf positions than gantry or collimator 
angle. OARs in close proximity to incident beams were most 
sensitive to changes in gantry angle. Work is ongoing to 
extend this study to a wider set of plans with the aim of 
quantifying site- and technique-specific estimates of 
treatment delivery uncertainties on advanced RT techniques. 
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Purpose/Objective: Dose rate is known to be an essential 
factor in radiobiology. As modern radiotherapy delivery 
techniques such as Volumetric Modulated Arc Therapy (VMAT) 
introduce variability to the dose rate, it is important to 
assess the changes in dose rate in VMAT treatment plans. 
Thus, in this work the SMCP framework was extended to 
assess dose rate during the application of a VMAT treatment 
plan. 
Materials and Methods: The SMCP framework is interfaced to 
the Treatment Planning System (TPS) Varian Eclipse and is 
used to calculate dose and dose rate distributions. For the 
latter, SMCP splits the VMAT plan file into individual plan 
files, each representing an arc segment between two 
consecutive DICOM control points. Each of these files 
contains the gantry angle and Multi-Leaf Collimator (MLC) 
position data of their respective arc segment, leaving other 
plan data untouched. In a next step, dose distributions are 
calculated in units of cGy per Monitor Unit (MU) for each arc 
segment independently by means of the SMCP on a Linux 
cluster. Resulting dose in each voxel is then multiplied by its 
corresponding MU rate per second as received from Eclipse, 
yielding dose rate distributions per arc segment.  
This approach was applied to a head and neck cancer 
patient. For this purpose, a full rotation VMAT arc plan to 
deliver 2 Gy per fraction as mean dose to the PTV was used. 
Machine dose rate was set to 600 MU per minute in this plan. 
For the full 178° VMAT, 399 MU were applied over a total 
time of 74.7 s. This led to 177 arc segments, for which the 
dose distributions were calculated to a statistical uncertainty 
of about 1% using 0.25cm³ calculation grid voxels. Data was 
plotted in terms of dose rate versus time within the 
calculation volume and PTV. 
Results: For the head and neck case selected, dose rates per 
segment reached up to 12.16 cGy/s within the full 
calculation volume. Within the PTV, the range extended from 
0.04 to 12.16 cGy/s. Mean PTV dose rate over the whole arc 
was 2.08 cGy/s. Maximal dose rate per segment within the 
PTV ranged from 3.6 cGy/s in arc segment 125 to 12.16 cGy/s 
in segment 65, while minimal PTV dose rate per segment 
ranged from 0.04 cGy/s in segment 118 to 0.18 cGy/s in 
segment 64. 
Conclusions: The SMCP framework is now able to assess the 
dose rate for each voxel in a calculation volume. A 
substantial variation of dose rate per segment was observed 
in the head and neck cancer VMAT treatment plan 
considered. 
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Purpose/Objective: The aim of this work is to establish an 
alternative method to evaluate differences between IMRT 
dose distributions; comparing Superposition Collapsed Cone 
(SCC) TPS dose calculations to Monte Carlo (MC) redundant 
calculations. MC is considered our reference calculation 
provided that is properly set up and validated with 
experimental measurements. We present here initial results 
for quantitative comparison of dose distributions based on 
DVH parameters. Gamma evaluation has been the most 
accepted tool during the last decades [1], but this kind of 
